Armata Pharmaceuticals

Armata has filed the complete phase‑3 protocol and responses to FDA feedback for the bacteriophage candidate AP‑SA02 to treat complicated S. aureus bacteremias. Four engineering runs have been completed in cGMP production in Los Angeles; production of clinical trial material and study start are planned for the second half of 2026. AP‑SA02 holds FDA designations Qualified Infectious Disease Product and Fast Track; the U.S. Department of Defense is funding development with an additional $2.5 million (total $28.7 million). Investors reacted positively, the share price rose markedly, and David House was promoted to CFO. » Plus sur de.investing.com

The FDA has granted fast-track status to Armata’s intravenous multi-phage candidate AP-SA02 for the treatment of complicated S. aureus bacteremias, enabling more frequent interaction with the agency, rolling review of approval, and potentially accelerated approval. AP-SA02 showed positive Phase 1b/2a results, and Armata plans a Phase 3 superiority study in the second half of 2026. Analysts mostly rate the stock a buy with price targets of $15 to $20, although the company was recently unprofitable and reported a loss per share of $4.80. » Plus sur de.investing.com

Armata Pharmaceuticals has scheduled its annual general meeting for June 11, 2026 at 8:30 a.m. Pacific Time at its headquarters in Los Angeles. Shareholders eligible to receive notice and vote are those recorded in the share register at the close of business on April 17, 2026; the deadline for shareholder proposals and director nominations is April 12, 2026 at 5:00 p.m. Pacific Time. The company also reported weak quarterly results: adjusted EPS of -$3.42 and revenue of $1.1 million, both well below expectations. » Plus sur de.investing.com